Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Fig. 1: Differential expression of TPX2 in pancreatic cancer.
Immunohistochemical detection of TPX2 expression in exemplary PDAC cases showing (a) high TPX2 expression and (b) low TPX2 expression. 200-fold magnification. Scale bars indicate 50 µm.
Fig. 2: High TPX2 expression is associated with dismal prognosis in 1st-line gemcitabine-treated pancreatic cancer patients.
Univariate analyses (Kaplan–Meier curves and log-rank tests) for PFS and OS in the gemcitabine 1st-line chemotherapy subgroup (a, b) as well as in the non-gemcitabine 1st-line chemotherapy subgroup (c, d), according to TPX2 expression. Crossed lines indicate censored cases.
Fig. 3: High TPX2 expression is associated with dismal prognosis in resected pancreatic cancer patients treated with adjuvant gemcitabine-based chemotherapy.
Univariate analyses (Kaplan–Meier curves and log-rank tests) for DFS and OS in the gemcitabine-based adjuvant treatment cohort (a, b) and the non-gemcitabine-based adjuvant treatment cohort (c, d) according to TPX2 expression, as well as in the gemcitabine-based treated (e, f) and the non-gemcitabine-based treated (g, h) validation cohorts. Crossed lines indicate censored cases. Association of TPX2 expression and 14 gene-based gemcitabine-resistance expression signature (i). Correlation of TPX2 expression and the expression of gemcitabine-resistance-associated genes (j).
Aguirre-Gamboa,
SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis.
2013, Pubmed
Aguirre-Gamboa,
SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis.
2013,
Pubmed
Byrum,
Mitotic regulators TPX2 and Aurora A protect DNA forks during replication stress by counteracting 53BP1 function.
2019,
Pubmed
Conroy,
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
2018,
Pubmed
Conroy,
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
2011,
Pubmed
Ewald,
H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation.
2007,
Pubmed
Galili,
heatmaply: an R package for creating interactive cluster heatmaps for online publishing.
2018,
Pubmed
Gao,
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.
2013,
Pubmed
Gomes-Filho,
Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer.
2020,
Pubmed
Haas,
Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer.
2017,
Pubmed
Heath,
The NCI Genomic Data Commons.
2021,
Pubmed
Hegewisch-Becker,
Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma.
2019,
Pubmed
Heidebrecht,
p100: a novel proliferation-associated nuclear protein specifically restricted to cell cycle phases S, G2, and M.
1997,
Pubmed
Heinemann,
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104).
2013,
Pubmed
Huang,
Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development.
2021,
Pubmed
Joukov,
Aurora-PLK1 cascades as key signaling modules in the regulation of mitosis.
2018,
Pubmed
Lens,
Shared and separate functions of polo-like kinases and aurora kinases in cancer.
2010,
Pubmed
Macarulla,
Management and supportive treatment of frail patients with metastatic pancreatic cancer.
2019,
Pubmed
Mizrahi,
Pancreatic cancer.
2020,
Pubmed
Neumayer,
TPX2: of spindle assembly, DNA damage response, and cancer.
2014,
Pubmed
Neumayer,
Targeting protein for xenopus kinesin-like protein 2 (TPX2) regulates γ-histone 2AX (γ-H2AX) levels upon ionizing radiation.
2012,
Pubmed
,
Xenbase
Oettle,
Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.
2013,
Pubmed
Park,
Pancreatic Cancer: A Review.
2021,
Pubmed
Song,
Plk1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer.
2013,
Pubmed
Stratford,
A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma.
2010,
Pubmed
Vallejo,
An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer.
2017,
Pubmed
Vena,
The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
2015,
Pubmed
Waddell,
Whole genomes redefine the mutational landscape of pancreatic cancer.
2015,
Pubmed
Wang,
Clinical value of Xenopus kinesin-like protein 2 as a prognostic marker in patients with digestive system cancers: a systematic review and meta-analysis.
2018,
Pubmed
,
Xenbase
Warner,
Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells.
2009,
Pubmed
Wei,
A 14-gene gemcitabine resistance gene signature is significantly associated with the prognosis of pancreatic cancer patients.
2021,
Pubmed
Xiong,
DiseaseMeth version 2.0: a major expansion and update of the human disease methylation database.
2017,
Pubmed
Yang,
The clinical significance and prognostic value of Xenopus kinesin-like protein 2 expressions in human tumors: A systematic review and meta-analysis.
2019,
Pubmed
,
Xenbase
Zhang,
DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma.
2012,
Pubmed
de Sousa Cavalcante,
Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer.
2014,
Pubmed
